Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 4/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.35 |
| ▸ | HTR2C | P28335 | 10/20 | 0.34 |
| ▸ | HTR2A | P28223 | 9/20 | 0.34 |
| ▸ | HTR2B | P41595 | 9/20 | 0.34 |
| ▸ | CLPP | Q16740 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23973230 | 0.89 | HPGD (0.40) | PARP1TNKSTNKS2HTR2CHTR2A | |
| SCHEMBL23973234 | 0.88 | HTR2C (0.41) | PARP1TNKSTNKS2HTR2CHTR2A | |
| SCHEMBL23973231 | 0.85 | TNKS (0.36) | PARP1TNKSTNKS2HTR2CHTR2A | |
| SCHEMBL30284329 | 0.85 | TNKS (0.36) | PARP1TNKSTNKS2HTR2CHTR2A | |
| SCHEMBL23972481 | 0.82 | HTR2C (0.44) | PARP1TNKSTNKS2HTR2CHTR2A | |
| SCHEMBL23973163 | 0.82 | HPGD (0.43) | PARP1TNKSTNKS2HTR2CHTR2A | |
| SCHEMBL23973236 | 0.81 | TNKS2 (0.39) | PARP1TNKSTNKS2HTR2CCLPP | |
| SCHEMBL23973237 | 0.81 | HTR2C (0.40) | PARP1TNKSTNKS2HTR2CHTR2A | |
| SCHEMBL23973233 | 0.81 | TNKS2 (0.39) | PARP1TNKSTNKS2HTR2CHTR2A | |
| SCHEMBL23973229 | 0.80 | TNKS (0.40) | PARP1TNKSTNKS2HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115427409-B | Pyrimidine-4 (3H) -one derivatives as TRPV4 antagonists | 拉夸里亚创药株式会社 | 2025-02-25 | — | — | CN | claimed |
| EP-4142874-B1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2026-04-22 | — | — | EP | disclosed |
| CN-115427409-B | Pyrimidine-4 (3H) -one derivatives as TRPV4 antagonists | 拉夸里亚创药株式会社 | 2025-02-25 | — | — | CN | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| CN-115776890-A | TRPV4 inhibitors as therapeutic agents for eye diseases | 拉夸里亚创药株式会社 | 2023-03-10 | — | — | CN | disclosed |
| WO-2021221169-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | PARP1 2542/4885TNKS 1079/4885TNKS2 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.